Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCs

18 Feb 2022

Abstract excerpt

No abstract is available from the source.

Topics

Join the communities discussing this publication.

CAR-T cell therapy research
Hemophilia Treatment and Research

Source

Identifiers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

PMID

35217482

DOI

10.1016/j.biomaterials.2022.121429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCsPMID 35217482Read ↗

Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia ASemantic proximity Read ↗

ssODN-Mediated In-Frame Deletion with CRISPR/Cas9 Restores FVIII Function in Hemophilia A-Patient-Derived iPSCs and ECsSemantic proximity Read ↗

Harnessing iPSCs, 3D organoids, and multiomics to model rare vascular diseases: Emerging new approach methodologies.Semantic proximity Read ↗

Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.Semantic proximity Read ↗

Phenotypic correction of murine hemophilia A using an iPS cell-based therapy.Semantic proximity Read ↗

Generation of a Syngeneic Heterozygous ACVRL1(wt/mut) Knockout iPS Cell Line for the In Vitro Study of HHT2-Associated Angiogenesis.Semantic proximity Read ↗

CRISPR/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a Fabry disease vasculopathy model derived from human induced pluripotent stem cellsSemantic proximity Read ↗

Endothelial cells derived from patients’ induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia ASemantic proximity Read ↗

Long-term correction of hemophilia A via integration of a functionally enhanced FVIII gene into the AAVS1 locus by nickase in patient-derived iPSCsSemantic proximity Read ↗

CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B TherapySemantic proximity Read ↗

FVIII interacts with cell surface to regulate endothelial cell functionalitySemantic proximity Read ↗

Generation of three lines from multiorgan venous and lymphatic defect syndrome patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.